Profiles

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles

• CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22

• FDG-PET/CT for Response to Cancer Therapy 2016-11-18

• UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014

Stage 2: Consensus Profiles

• 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20

• MR Elastography of the Liver 2018-05-02

• CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-02-11

• SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26

• Checklist - SPECT Profile Conformance

• CT Tumor Volumetry for Advanced Disease 2016-11-21b

• Checklist - CT Tumor Volumetry for Advanced Disease

• MR DCE Quantification v1.0 2012-08-08

Stage 1: Public Comment Profiles

Submit comments using the online form: http://tinyurl.com/QIBA-Public-Comment-Form
(Note: each form accommodates 10 comments; submit additional forms as necessary)

• There are currently no Profiles open for Public Comment

Public Comment closed for the following Profiles (comment resolution is underway on the corresponding committee page):

• fMRI 2017-06-19 (Closed on December 31, 2017)
• PET Amyloid: 18F-labeled PET Tracers Targeting Amyloid as an Imaging Biomarker - 2018-05-02 (Closed on September 15, 2017)
• MR Elastography 2017-08-15 (Closed on September 15, 2017)
• MR DWI 2017-04-27 (Closed on August 25, 2017)

Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL

Example:

QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement

• Industry
• Clinical Sites
• Additional letters of support can be found here

See Also

• How to use QIBA Profiles
• Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
• Profile Conformance describes how sites and products claim conformance to a Profile.
• QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)

• Work Product for Review